



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Sette *et al.*

Appl. No. 09/189,702

Filed: November 10, 1998

For: **HLA Binding Peptides and
Their Uses**

Confirmation No. 5779

Art Unit: 1644

Examiner: Schwadron, Ronald B.

Atty. Docket: 2060.0370001/EKS/VSR

Second Supplemental Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450
Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each document is provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Form PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

Sette *et al.*
Appl. No. 09/189,702

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed along with a Request for Continued Examination under 37 C.F.R. § 1.114. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



~~FE~~ Eric K. Steffe 45,986
Attorney for Applicants
Registration No. 36,688

Date: July 6, 2004
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
284494_1.DOC

FORM PTO-1449

ATTY. DOCKET NO.
2060.0370001/EKS/VSAPPLICATION NO.
09/189,702SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTFIRST NAMED INVENTOR
Sette *et al.*FILING DATE
November 10, 1998ART UNIT
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	WO 01/41788 A1	06/14/2001	WIPO			Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>1</u>	Gnjatic, S., <i>et al.</i> , "Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules," <i>Eur. J. Immunol.</i> 25:1638-1642, VCH Verlagsgesellschaft mbH (1995)
	AS	<u>1</u>	Harlow, E., <i>et al.</i> , "Molecular Cloning and In Vitro Expression of a cDNA Clone for Human Cellular Tumor Antigen p53," <i>Mol. Cell. Biol.</i> 5:1601-1610, American Society for Microbiology (1985)
	AT	<u>1</u>	Harris, N., <i>et al.</i> , "Molecular Basis for Heterogeneity of the Human p53 Protein," <i>Mol. Cell. Biol.</i> 6:4650-4656, American Society for Microbiology (1986)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0370001/EKS/VS	APPLICATION NO. 09/189,702
	FIRST NAMED INVENTOR Sette <i>et al.</i>	
	FILING DATE November 10, 1998	ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	Lamb, P., and Crawford, L., "Characterization of the Human p53 Gene," <i>Mol. Cell. Biol.</i> 6:1379-1385, American Society for Microbiology (1986)
	AS	2	Röpke, M., <i>et al.</i> , "T Cell-Mediated Cytotoxicity Against p53-Protein Derived Peptides in Bulk and Limiting Dilution Cultures of Healthy Donors," <i>Scand. J. Immunol.</i> 42:98-103, Blackwell Science Limited (1995)
	AT	2	Toes, R.E.M., <i>et al.</i> , "Enhancement of Tumor Outgrowth Through CTL Tolerization After Peptide Vaccination Is Avoided by Peptide Presentation on Dendritic Cells," <i>J. Immunol.</i> 160:4449-4456, The American Association of Immunologists (1998)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
2060.0370001/EKS/VSAPPLICATION NO.
09/189,702FIRST NAMED INVENTOR
Sette *et al.*FILING DATE
November 10, 1998ART UNIT
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>3</u>	Vojtesek, B., <i>et al.</i> , "Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein," <i>Oncogene</i> 10:389-393, Stockton Press (1995)
	AS	<u>3</u>	Zakut-Houri, R., <i>et al.</i> , "Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells," <i>EMBO J</i> 4:1251-1255, IRL Press Limited (1985)
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.